ArticleAnnals of the rheumatic diseases2014
Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database.
Article in Annals of the rheumatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Comorbidities in polymyalgia rheumatica: a systematic review.Arthritis research & therapy · 2018Pooled it
- Trial
- Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway.Rheumatology (Oxford, England) · 2026Article
- Serum protein biomarkers for polymyalgia rheumatica: a case-control study.Frontiers in immunology · 2026Article
- Patient experiences of PMR: a qualitative narrative literature review.Rheumatology advances in practice · 2026Article
- Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.Journal of clinical medicine · 2025Review
- Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization study.Cancer pathogenesis and therapy · 2024Article
- The contributions of deleterious rare alleles in NLRP12 and inflammasome-related genes to polymyalgia rheumatica.Scientific reports · 2024Article
- Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET/CT.Frontiers in medicine · 2024Article
- Pre-existing musculoskeletal pain and its association with mortality in newly diagnosed co-morbid conditions: an electronic health record cohort study.Rheumatology advances in practice · 2024Article
- Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy.Frontiers in pharmacology · 2023Review
- Case Report and Literature Review of an Atypical Polymyalgia Rheumatica and Its Management.International medical case reports journal · 2023Article
- The fast-track outpatient clinic significantly decreases hospitalisation rates among polymyalgia rheumatica patients.BMC rheumatology · 2021Article
- The frequency of occult solid malignancy in patients with polymyalgia rheumatica-like symptoms.Therapeutic advances in musculoskeletal disease · 2021Article
- A Case of Localized Prostate Cancer Associated with Polymyalgia Rheumatica with Marked Symptomatic Improvement after Robot-Assisted Radical Prostatectomy.Case reports in urology · 2021Article
- "The added value of 18f-FDG PET/CT in the assessment of onset and steroid resistant polimyalgia rheumatica".PloS one · 2021Article
- Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.Journal of translational autoimmunity · 2021Article
- Prevalence of Newly Diagnosed Malignancies in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis, Comparison of 18F-FDG PET/CT Scan with Chest X-ray and Abdominal Ultrasound: Data from a 40 Week Prospective, Exploratory, Single Centre Study.Journal of clinical medicine · 2020Article
- Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome.Internal medicine (Tokyo, Japan) · 2020Article
- A paraneoplastic syndrome exacerbated by checkpoint inhibition therapy.Proceedings (Baylor University. Medical Center) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate the incidence of new cancer diagnoses in a community sample of patients with polymyalgia rheumatica (PMR).
methodsAll incident cases of PMR in the UK General Practice Research Database (GPRD) (1987-99), without pre-existing cancer or vascular disease and treated with corticosteroids (n=2877) were matched with up to five age, sex and GP practice patients without PMR (n=9942). Participants were followed up until first cancer diagnosis, death, transfer out of the database or end of available records.
resultsThe mean age of the sample was 71.6 years (SD 9.0), 73% were female. Median follow-up time was 7.8 years (IQR 3.4, 12.3). 667 (23.2%) people with a PMR diagnosis developed cancer compared with 1938 (19.5%) of those without PMR. There was an interaction between PMR status and time. In the first 6 months after diagnosis, those with a PMR diagnosis were significantly more likely to receive a cancer diagnosis (adjusted HR (95% CI): 1.69 (1.18 to 2.42)). The number of events was small, but occurrences of prostate, blood, lymph nodes, female reproductive and nervous system cancers may be more common in those with PMR in the first 6 months after PMR diagnosis.
conclusionsAn increase in the rate of cancer diagnoses was noted in the first 6 months of observation, but we were unable to determine whether the cancer incidence in PMR was different from controls, beyond this time point. Clinicians should ensure they fully exclude cancer as a cause of PMR-like symptoms and monitor patients for possible malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.